Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2026 Q2 | Aug 31, 2026 | Meridian Contrarian Fund | 17.8% | - | BB, CACI, CEVA, CRC, PDFS, TRMB | AI, contrarian, Recovery, semiconductors, small caps, SMID Cap, technology, value | CACI TRMB CRC PDFS CEVA BB |
View | |
| 2025 Q2 | Aug 2, 2025 | Meridian Growth Fund | 4.1% | - | ALGN, CARG, CHDN, COO, CW, DKNG, DOCS, EEFT, FSS, GFS, HALO, RBA, SPT, TRMB, ZD | growth, healthcare, industrials, Quality, risk management, small cap, technology | The fund's investment approach is grounded in investing in high-quality businesses with recurring revenue and sustainable competitive advantages. This emphasis on quality businesses with stable revenues and attractive valuations remains the core strategy going forward. | DKNG FSS CW COO HALO ZD COO HALO ZD |
View |
| 2026 Q2 | Jul 31, 2026 | Sycamore Mid Cap Value Equity Strategy | 9.6% | 14.6% | DVN, EXE, FCN, KNX, LHX, MCHP, MKSI, MOH, STLD, TRMB, WDC | AI Skepticism, Market Concentration, mid cap, Quality, Risk Appetite, semiconductors, small caps, value | View | ||
| 2026 Q2 | Jul 25, 2026 | Meridian Growth Fund | 19.1% | - | DFTX, GFS, HNGE, TNDM, TRMB | Biotechnology, growth, Medical Devices, Quality, rates, Risk Appetite, semiconductors, SMID Cap | GFS DFTX HNGE TNDM TRMB |
View | |
| 2025 Q2 | Jul 16, 2025 | ARK Invest | 34.6% | 15.4% | ACHR, AMD, AMZN, AVAV, COIN, CRCL, CRSP, HOOD, KTOS, PLTR, RBLX, RKLB, ROKU, SHOP, TEM, TER, TRMB, TSLA, TTD, TWST | AI, crypto, defense, Genomics, growth, innovation, Robotics, technology | ARK views artificial intelligence as one of its Five Innovation Platforms that could play an outsized role in pulling the economy out of the rolling recession. The firm believes AI, along with other innovation platforms, could catalyze productivity gains and accelerate economic growth during turbulent times when consumers and businesses are willing to change how they operate. | View | |
| 2024 Q1 | Apr 15, 2024 | Meridian Growth Fund | 6.8% | 0.0% | ACVA, ALIT, CARG, EEFT, IRDM, MATX, QDEL, RBA, SHC, ST, STE, TRMB, ZD | growth, Quality, Recurring Revenue, risk management, small caps, technology | QuidelOrtho Corporation is a global leader in the diagnostics industry following the merger of Quidel and Ortho Clinical Diagnostics. The company faced challenges from a dramatic slowdown in Covid-19 testing volumes but maintains steady performance in its core clinical diagnostic division with EBITDA margins north of 20%. | RBA ACVA TRMB SHC IRDM QDEL |
View |
| 2025 Q1 | Mar 31, 2025 | Meridian Growth Fund | -8.0% | -8.0% | ALIT, CARG, CHDN, COO, EEFT, HALO, OKTA, RBA, STE, TNDM, TRMB, WAY, ZD | Biotechnology, cybersecurity, growth, healthcare, Quality, Resilience, small caps, tariffs | The fund focuses on small-cap growth investing through the Russell 2500 Growth Index benchmark, with emphasis on high-quality businesses with recurring revenue and sustainable competitive advantages. The strategy demonstrated resilience during the quarter's market decline, outperforming on six of seven days when the index declined 2% or more. | CARG TNDM ZD RBA HALO OKTA |
View |
| 2024 Q4 | Feb 10, 2025 | Meridian Growth Fund | -0.8% | 6.3% | ALIT, CARG, CHDN, DOCS, EEFT, GNRC, OKTA, RBA, RELY, ST, STE, TMDX, TRMB, ZD | growth, healthcare, industrials, Quality, small caps, technology | The portfolio's largest allocation with historically attractive valuations below long-term averages. Utilization has recovered above pre-pandemic levels and investor interest in biotechnology is showing signs of revival. | CARG RELY DOCS STE ST TMDX |
View |
| 2023 Q4 | Dec 31, 2023 | Meridian Growth Fund | 6.8% | 0.0% | ALIT, CARG, CHDN, EEFT, FOXF, GOOS, HSIC, MATX, RBA, ST, STE, TRMB, ZD | growth, industrials, Quality, small caps, technology | The Fund's investment approach focuses on high-quality companies with recurring revenue and sustainable competitive advantages. The strategy emphasizes building an enduring portfolio that can mitigate capital losses during turbulent bear market environments. | MATX EEFT CARG HSIC FOXF GOOS.TO |
View |
| 2025 Q3 | Oct 24, 2025 | Meridian Growth Fund | -1.8% | - | ALGN, ALIT, ALKT, CARG, CHDN, COO, DT, GFS, HALO, MDGL, RELY, SPT, STE, TRMB, ZD | AI, growth, healthcare, industrials, Quality, small caps, SMID, technology | The fund sees signs of exuberance and speculative behavior in AI infrastructure ecosystem, particularly in technology and industrial sectors. While AI remains transformative long-term, valuations have become disconnected from fundamentals with companies exceeding $10 billion market caps lacking profits or revenues. The fund remains disciplined and unlikely to pursue high-momentum AI names without meaningful revenues or profitability. | ZD HALO MDGL ALGN SPT ALIT |
View |
| 2025 Q3 | Oct 15, 2025 | ARK Invest | - | - | ACHR, AMD, AMZN, AVAV, COIN, CRSP, HOOD, KTOS, PLTR, PSNL, RBLX, RKLB, ROKU, RXRX, SHOP, TEM, TER, TRMB, TSLA, TWST | AI, crypto, defense, Genomics, growth, innovation, Robotics, technology | ARK views artificial intelligence as one of the Five Innovation Platforms that could play an outsized role in pulling the economy out of the rolling recession. The firm expects AI to accelerate productivity gains and economic growth, particularly as businesses harness new technologies to increase productivity and protect margins during periods of pricing power loss. | View | |
| 2025 Q4 | Jan 21, 2026 | Meridian Growth Fund | -0.4% | -6.4% | ABT, CERT, CHDN, COO, DOCS, DT, EXAS, GFS, GMED, RELY, SAIC, TNDM, TPB, TRMB, VCYT | growth, healthcare, Medical Devices, Quality, small caps, technology | Healthcare was the portfolio's largest allocation and top-performing sector for the quarter, with the fund maintaining an overweight position. The manager views healthcare as undervalued relative to long-term fundamentals after lagging the broader market for four years. Several healthcare holdings contributed positively including medical device companies and diagnostics firms. The fund's investment approach emphasizes high-quality businesses with recurring revenue, sustainable competitive advantages, and strong balance sheets. However, the quarter saw relative outperformance by lower-quality stocks which created a modest headwind to performance given the portfolio's quality bias. The fund focuses on small-cap growth investments, benchmarked against the Russell 2500 Growth Index. Small caps delivered solid annual returns of 12.8% for the year, though below large-cap returns, with value outperforming growth in the quarter. | View | |
| 2025 Q4 | Jan 14, 2026 | ARK Invest | 0.0% | 0.0% | ACHR, AMD, AVAV, COIN, CRSP, DE, GH, GOOG, HOOD, KTOS, PLTR, RBLX, RKLB, ROKU, SHOP, TEM, TER, TRMB, TSLA, TWST | AI, crypto, defense, Genomics, innovation, productivity, Robotics, technology | ARK believes convergences among major platforms like AI, robotics, energy storage, public blockchain technology, and multiomics sequencing should accelerate non-farm productivity growth to 4–6% on a year-over-year basis. AI-related spending boom on data centers and power plants began in late 2022. Strong demand for AI-related chip testing and semiconductor testing across compute, networking, and memory. Robotics is identified as one of the major transformative innovation platforms that should converge with AI and other technologies to drive productivity gains. The ARK Autonomous Technology and Robotics ETF focuses on companies developing autonomous mobility, humanoid robots, and intelligent devices. Energy storage is highlighted as one of the key transformative innovation platforms that will converge with AI, robotics, blockchain, and multiomics sequencing to accelerate productivity growth and economic transformation in the coming years. ARK sees favorable policy shifts around crypto as supportive headwinds shifting into structural tailwinds for innovation. Coinbase faced challenges from weakness in crypto market trading activity, with quarterly spot trading volumes declining 9% quarter-over-quarter. The firm maintains exposure through Bitcoin ETFs and crypto-related companies. Multiomics sequencing is identified as one of the major transformative platforms. The genomics space benefited from increasingly positive sentiment following Abbott's acquisition of Exact Sciences. Companies like Guardant Health and Natera showed strong performance with significant revenue growth and clinical trial successes. Defense spending represents a significant opportunity with the U.S. Army announcing plans to purchase at least one million drones in the next 2–3 years. Companies like Kratos Defense, AeroVironment, and Rocket Lab are positioned in this space, though innovation-based defense stocks experienced broad sell-offs during the quarter. | View | |
| 2024 Q3 | Sep 30, 2024 | Meridian Growth Fund | 6.8% | 0.0% | CARG, CHDN, COO, DOCS, EEFT, GFS, OKTA, RBA, SMAR, ST, STE, TRMB, ZD | growth, healthcare, semiconductors, small caps, software, technology | The fund is gaining confidence in healthcare outlook after years of underperformance. Healthcare stocks are trading slightly below historical valuations with stable to improving fundamentals. Recent company checks reinforce a sound basis for the portfolio's overweight position in this sector. | COO SMAR DOCS GFS ZD OKTA |
View |
| 2023 Q3 | Sep 30, 2023 | Meridian Growth Fund | 6.8% | 0.0% | ALEX, CACI, CCJ, DBRG, FCNCA, PRGO, SGH, TAP, TRMB, VICI | contrarian, energy, financials, small caps, technology, value | View | ||
| 2024 Q2 | Jun 30, 2024 | Meridian Growth Fund | 6.8% | 0.0% | ACVA, AGIO, ALIT, CARG, CHDN, CHWY, EEFT, RBA, RELY, SMAR, ST, STE, TMDX, TRMB, ZD | consumer discretionary, growth, healthcare, industrials, Quality, small cap, technology | The fund holds Transmedics Group, a medical technology company with a differentiated capability to facilitate organ transplants through their Organ Care System (OCS). The company reported increased adoption and buildout of its OCS platform with strong top-line growth and profitability metrics ahead of plan. | RELY TRMB ALIT AGIO CHWY TMDX |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Fund Letters | Meridian Contrarian Fund | Trimble Inc. | Scientific & Technical Instruments | Technology Hardware, Storage & Peripherals | Bull | NASDAQ | Agriculture Technology, competitive moat, Construction Technology, Equity, Geospatial, Hardware-Software Integration, Positioning Technology, proprietary data, secular growth, Transportation, workflow automation | View Pitch |
| Jul 28, 2026 | Fund Letters | Meridian Growth Fund | Trimble Inc. | Scientific & Technical Instruments | Application Software | Bull | NASDAQ | Construction Technology, Digital transformation, margin expansion, recurring revenue, SaaS, Software, subscription revenue, vertical software, workflow solutions | View Pitch |
| Apr 13, 2026 | Fund Letters | Meridian Growth Fund | Trimble, Inc. | Technology Hardware & Equipment | Technology Hardware, Storage & Peripherals | Bull | NASDAQ | Agricultural Technology, Construction Technology, Geospatial, Industrial technology, recurring revenue, subscription model, Transportation | View Pitch |
| Apr 13, 2026 | Fund Letters | Meridian Growth Fund | Trimble, Inc. | Information Technology | Technology Hardware, Storage & Peripherals | Bull | NASDAQ | Agricultural, construction, gross margins, Industrial technology, Joint venture, recurring revenue, subscription model, valuation discount | View Pitch |
| Aug 13, 2025 | Seeking Alpha | Kamil Magomedov | Trimble Inc. | Information Technology | Scientific & Technical Instruments | Bull | NASDAQ | — | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||